Apellis Announces Results from New Global Survey Conducted by The Harris Poll Revealing the Emotional Burden and Impact on Independence Caused by Geographic Atrophy (GA)GlobeNewsWire • 04/21/22
Why Is Apellis Pharmaceuticals, Inc. (APLS) Up 8.9% Since Last Earnings Report?Zacks Investment Research • 03/30/22
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 03/28/22
Moore Kuehn, PLLC Encourages Investors of Apellis Pharmaceuticals, Inc. to Contact Law FirmNewsfile Corp • 03/17/22
Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy StudiesBenzinga • 03/16/22
Apellis shares jump 6% after the company announces new new data for its geographic atrophy drugMarket Watch • 03/16/22
Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)GlobeNewsWire • 03/16/22
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/28/22
Apellis Pharmaceuticals to Host Conference Call on February 28, 2022 to Discuss Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/22/22
Apellis Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/22
Apellis and Sobi Report Empaveli™ (pegcetacoplan) Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient PopulationGlobeNewsWire • 12/13/21